- Home
- IOVA vs DVAX Comparison
IOVA vs DVAX Comparison
Compare IOVA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- DVAX
- Stock Information
- Founded
- IOVA 2007
- DVAX 1996
- Country
- IOVA United States
- DVAX United States
- Employees
- IOVA N/A
- DVAX N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- DVAX Health Care
- Exchange
- IOVA Nasdaq
- DVAX Nasdaq
- Market Cap
- IOVA 975.1M
- DVAX 1.3B
- IPO Year
- IOVA N/A
- DVAX 2004
- Fundamental
- Price
- IOVA $2.24
- DVAX $9.75
- Analyst Decision
- IOVA Buy
- DVAX Buy
- Analyst Count
- IOVA 11
- DVAX 4
- Target Price
- IOVA $11.90
- DVAX $26.50
- AVG Volume (30 Days)
- IOVA 9.5M
- DVAX 2.0M
- Earning Date
- IOVA 11-06-2025
- DVAX 11-06-2025
- Dividend Yield
- IOVA N/A
- DVAX N/A
- EPS Growth
- IOVA N/A
- DVAX N/A
- EPS
- IOVA N/A
- DVAX N/A
- Revenue
- IOVA $241,525,000.00
- DVAX $316,268,000.00
- Revenue This Year
- IOVA $67.40
- DVAX $23.23
- Revenue Next Year
- IOVA $56.32
- DVAX $16.57
- P/E Ratio
- IOVA N/A
- DVAX N/A
- Revenue Growth
- IOVA 636.99
- DVAX 26.66
- 52 Week Low
- IOVA $1.64
- DVAX $9.20
- 52 Week High
- IOVA $12.51
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- IOVA 44.45
- DVAX 43.66
- Support Level
- IOVA $2.19
- DVAX $9.20
- Resistance Level
- IOVA $2.38
- DVAX $9.94
- Average True Range (ATR)
- IOVA 0.14
- DVAX 0.31
- MACD
- IOVA -0.01
- DVAX -0.01
- Stochastic Oscillator
- IOVA 32.05
- DVAX 50.00
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.